RESUMEN
AIMS: Dose escalation at the initiation of allopurinol therapy can be protracted and resource intensive. Tools to predict the allopurinol doses required to achieve target serum urate concentrations would facilitate the implementation of more efficient dose-escalation strategies. The aim of this research was to develop and externally evaluate allopurinol dosing tools, one for use when the pre-urate-lowering therapy serum urate is known (Easy-Allo1) and one for when it is not known (Easy-Allo2). METHODS: A revised population pharmacokinetic-pharmacodynamic model was developed using data from 653 people with gout. Maintenance doses to achieve the serum urate target of <0.36 mmol L-1 in >80% of individuals were simulated and evaluated against external data. The predicted and observed allopurinol doses were compared using the mean prediction error (MPE) and root mean square error (RMSE). The proportion of Easy-Allo predicted doses within 100 mg of the observed was quantified. RESULTS: Allopurinol doses were predicted by total body weight, baseline urate, ethnicity and creatinine clearance. Easy-Allo1 produced unbiased and suitably precise dose predictions (MPE 2 mg day-1 95% confidence interval [CI] -13-17, RMSE 91%, 90% within 100 mg of the observed dose). Easy-Allo2 was positively biased by about 70 mg day-1 and slightly less precise (MPE 70 mg day-1 95% CI 52-88, RMSE 131%, 71% within 100 mg of the observed dose). CONCLUSIONS: The Easy-Allo tools provide a guide to the allopurinol maintenance dose requirement to achieve the serum urate target of <0.36 mmol L-1 and will aid in the development of novel dose-escalation strategies for allopurinol therapy.
Asunto(s)
Alopurinol , Relación Dosis-Respuesta a Droga , Supresores de la Gota , Gota , Modelos Biológicos , Ácido Úrico , Alopurinol/administración & dosificación , Alopurinol/farmacocinética , Humanos , Gota/tratamiento farmacológico , Gota/sangre , Supresores de la Gota/administración & dosificación , Supresores de la Gota/farmacocinética , Ácido Úrico/sangre , Masculino , Femenino , Persona de Mediana Edad , Anciano , Adulto , Cálculo de Dosificación de Drogas , Simulación por ComputadorRESUMEN
AIMS: The aim of this study was to estimate adherence to urate-lowering therapy (ULT), predominately allopurinol, from Australia's Pharmaceutical Benefits Scheme (PBS) claims database in association with (1) patient-reported doses and (2) World Health Organization's (WHO) defined daily doses (DDD), namely, allopurinol (400 mg/day) or febuxostat (80 mg/day). METHODS: Proportion of days covered (PDC) was calculated in 108 Gout App (Gout APP) trial participants with at least two recorded ULT dispensings in an approximately 12-month period before provision of intervention or control apps. Adherence was defined as PDC ≥80%. We measured the correlation between the two methods of calculating PDC using a Wilcoxon signed rank test. Agreement between ULT-taking status (self-reports) and ULT-dispensed status (PBS records) was tested with Cohen's kappa (κ), and positive and negative percent agreement. RESULTS: Allopurinol was prescribed in 93.5% of participants taking ULT. Their self-reported mean daily dose (SD) was 291 (167) mg/day. Mean PDC (SD) for allopurinol was 83% (21%) calculated using self-reported dose, and 63% (24%) using WHO's DDD. Sixty-three percent of allopurinol users were identified as adherent (PDC ≥80%) using self-reported dose. There was good agreement between self-reported ULT use and PBS dispensing claims (κ = 0.708, P < .001; positive percent agreement = 90%, negative percent agreement = 82%). CONCLUSIONS: Participant-reported allopurinol daily doses, in addition to PBS dispensing claims, may enhance confidence in estimating PDC and adherence compared to using DDD. This approach improves adherence estimations from pharmaceutical claims datasets for medications where daily doses vary between individuals or where there is a wide therapeutic dose range.
Asunto(s)
Alopurinol , Febuxostat , Supresores de la Gota , Gota , Cumplimiento de la Medicación , Autoinforme , Ácido Úrico , Humanos , Gota/tratamiento farmacológico , Gota/sangre , Alopurinol/administración & dosificación , Alopurinol/uso terapéutico , Supresores de la Gota/administración & dosificación , Supresores de la Gota/uso terapéutico , Cumplimiento de la Medicación/estadística & datos numéricos , Australia , Masculino , Femenino , Persona de Mediana Edad , Febuxostat/administración & dosificación , Febuxostat/uso terapéutico , Autoinforme/estadística & datos numéricos , Ácido Úrico/sangre , Anciano , Adulto , Bases de Datos FactualesAsunto(s)
Alopurinol , Quimioterapia Combinada , Insuficiencia Renal Crónica , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Alopurinol/uso terapéutico , Alopurinol/administración & dosificación , Método Doble Ciego , Insuficiencia Renal Crónica/tratamiento farmacológico , Insuficiencia Renal Crónica/complicacionesRESUMEN
BACKGROUND: The CRUCIAL trial (NCT04217421) is investigating the effect of postnatal and perioperative administration of allopurinol on postoperative brain injury in neonates with critical congenital heart disease (CCHD) undergoing cardiac surgery with cardiopulmonary bypass (CPB) shortly after birth. OBJECTIVE: This study aimed to characterize the pharmacokinetics (PK) of allopurinol and oxypurinol during the preoperative, intraoperative, and postoperative phases in this population, and to evaluate target attainment of the current dosing strategy. METHODS: Nonlinear mixed-effects modeling was used to develop population PK models in 14 neonates from the CRUCIAL trial who received up to five intravenous allopurinol administrations throughout the postnatal and perioperative periods. Target attainment was defined as achieving an allopurinol concentration >2 mg/L in at least two-thirds of the patients during the first 24 h after birth and between the start and 36 h after cardiac surgery with CPB. RESULTS: A two-compartment model for allopurinol was connected to a one-compartment model for oxypurinol with an auto-inhibition effect on the conversion, which best described the PK. In a typical neonate weighing 3.5 kg who underwent cardiac surgery at a postnatal age (PNA) of 5.6 days, the clearance (CL) of allopurinol and oxypurinol at birth was 0.95 L/h (95% confidence interval 0.75-1.2) and 0.21 L/h (0.17-0.27), respectively, which subsequently increased with PNA to 2.97 L/h and 0.41 L/h, respectively, before CPB. During CPB, allopurinol and oxypurinol CL decreased to 1.38 L/h (0.9-1.87) and 0.12 L/h (0.05-0.22), respectively. Post-CPB, allopurinol CL increased to 2.21 L/h (1.74-2.83), while oxypurinol CL dropped to 0.05 L/h (0.01-0.1). Target attainment was 100%, 53.8%, and 100% at 24 h postnatally, 24 h after the start of CPB, and 36 h after the end of cardiac surgery, respectively. The combined concentrations of allopurinol and oxypurinol maintained ≥ 90% inhibition of xanthine oxidase (IC90XO) throughout the postnatal and perioperative period. CONCLUSIONS: The minimal target concentration of allopurinol was not achieved at every predefined time interval in the CRUCIAL trial; however, the dosing strategy used was deemed adequate, since it yielded concentrations well exceeding the IC90XO. The decreased CL of both compounds during CPB suggests influence of the hypothermia, hemofiltration, and the potential sequestration of allopurinol in the circuit. The reduced CL of oxypurinol after CPB is likely attributable to impaired kidney function.
Asunto(s)
Alopurinol , Puente Cardiopulmonar , Cardiopatías Congénitas , Modelos Biológicos , Oxipurinol , Humanos , Alopurinol/farmacocinética , Alopurinol/administración & dosificación , Puente Cardiopulmonar/métodos , Recién Nacido , Cardiopatías Congénitas/cirugía , Oxipurinol/farmacocinética , Masculino , Femenino , Procedimientos Quirúrgicos Cardíacos/métodosRESUMEN
INTRODUCTION: Gout is one of the most common forms of arthritis worldwide. Gout is particularly prevalent in Aotearoa/New Zealand and is estimated to affect 13.1% of Maori men, 22.9% of Pacific men and 7.4% of New Zealand European men. Effective long-term treatment requires lowering serum urate to <0.36 mmol/L. Allopurinol is the most commonly used urate-lowering medication worldwide. Despite its efficacy and safety, the allopurinol dose escalation treat-to-target serum urate strategy is difficult to implement and there are important inequities in allopurinol prescribing in Aotearoa. The escalation strategy is labour intensive, time consuming and costly for people with gout and the healthcare system. An easy and effective way to dose-escalate allopurinol is required, especially as gout disproportionately affects working-age Maori men and Pacific men, who frequently do not receive optimal care. METHODS AND ANALYSIS: A 12-month non-inferiority randomised controlled trial in people with gout who have a serum urate ≥ 0.36 mmol/l will be undertaken. 380 participants recruited from primary and secondary care will be randomised to one of the two allopurinol dosing strategies: intensive nurse-led treat-to-target serum urate dosing (intensive treat-to-target) or protocol-driven dose escalation based on dose predicted by an allopurinol dosing model (Easy-Allo). The primary endpoint will be the proportion of participants who achieve target serum urate (<0.36 mmol/L) at 12 months. ETHICS AND DISSEMINATION: The New Zealand Northern B Health and Disability Ethics Committee approved the study (2022 FULL 13478). Results will be disseminated in peer-reviewed journals and to participants. TRIAL REGISTRATION NUMBER: ACTRN12622001279718p.
Asunto(s)
Alopurinol , Supresores de la Gota , Gota , Ácido Úrico , Humanos , Alopurinol/administración & dosificación , Alopurinol/uso terapéutico , Gota/tratamiento farmacológico , Gota/sangre , Nueva Zelanda , Supresores de la Gota/administración & dosificación , Supresores de la Gota/uso terapéutico , Ácido Úrico/sangre , Masculino , Relación Dosis-Respuesta a Droga , Adulto , Estudios de Equivalencia como Asunto , FemeninoRESUMEN
INTRODUCTION: The aim of the study was to explore the association between urate-lowering agents and reduced response to erythropoietin-stimulating agents in patients suffering from chronic kidney disease G5. METHODS: We conducted a cross-sectional, multicenter study in Japan between April and June 2013, enrolling patients aged 20 years or older with an estimated glomerular filtration rate of ≤15 mL/min/1.73 m2. Exclusion criteria encompassed patients with a history of hemodialysis, peritoneal dialysis, or organ transplantation. The patients were categorized into four groups based on the use of urate-lowering drugs: high-dose allopurinol (>50 mg/day), low-dose allopurinol (≤50 mg/day), febuxostat, and no-treatment groups. We used a multivariable logistic regression model, adjusted for covariates, to determine the odds ratio (OR) for erythropoietin hyporesponsiveness, defined by an erythropoietin resistance index (ERI) of ≥10, associated with urate-lowering drugs. RESULTS: A total of 542 patients were included in the analysis, with 105, 36, 165, and 236 patients in the high-dose allopurinol, low-dose allopurinol, febuxostat, and no-treatment groups, respectively. The median and quartiles of ERIs were 6.3 (0, 12.2), 3.8 (0, 11.2), 3.4 (0, 9.8), and 4.8 (0, 11.2) in the high-dose allopurinol, low-dose allopurinol, febuxostat, and no-treatment groups, respectively. The multivariate regression model showed a statistically significant association between the high-dose allopurinol group and erythropoietin hyporesponsiveness, compared to the no-treatment group (OR = 1.98, 95% confidence interval: 1.10-3.57). CONCLUSIONS: Our study suggests that the use of high-dose allopurinol exceeding the optimal dose may lead to hyporesponsiveness to erythropoiesis-stimulating agents.
Asunto(s)
Alopurinol , Eritropoyetina , Insuficiencia Renal Crónica , Humanos , Masculino , Femenino , Alopurinol/administración & dosificación , Alopurinol/uso terapéutico , Persona de Mediana Edad , Anciano , Estudios Transversales , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/tratamiento farmacológico , Eritropoyetina/administración & dosificación , Supresores de la Gota/administración & dosificación , Supresores de la Gota/uso terapéutico , Adulto , Relación Dosis-Respuesta a Droga , Ácido Úrico/sangre , Hematínicos/administración & dosificación , Hematínicos/uso terapéutico , Japón , Febuxostat/administración & dosificación , Febuxostat/uso terapéuticoRESUMEN
Guidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the incidence and outcome of TLS in AML patients. We analyzed 145 patients with AML who underwent induction therapy before the approval of rasburicase to evaluate the incidence of TLS and the necessity of rasburicase as prophylaxis. Three patients had already developed clinical TLS (CTLS) at diagnosis of AML, and another three developed CTLS after the initiation of chemotherapy. In patients without TLS at diagnosis of AML, the risk for developing TLS was classified as high in 44 patients, intermediate in 41 and low in 57, according to the current guidelines. Allopurinol alone was administered to prevent hyperuricemia in all patients. All three patients who developed CTLS after diagnosis of AML were at high risk of TLS, and had elevated serum creatinine levels and a WBC count greater than 200,000 per microliter at diagnosis of AML. Allopurinol may be insufficient to prevent TLS in high-risk patients with renal dysfunction at diagnosis of AML, especially those with a high tumor burden and a WBC count of 200,000 or more, which indicates that prophylactic administration of rasburicase should be considered.
Asunto(s)
Alopurinol , Leucemia Mieloide Aguda , Síndrome de Lisis Tumoral , Urato Oxidasa , Humanos , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/prevención & control , Urato Oxidasa/uso terapéutico , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/complicaciones , Masculino , Femenino , Persona de Mediana Edad , Alopurinol/uso terapéutico , Alopurinol/administración & dosificación , Anciano , Adulto , Quimioterapia de Inducción , Anciano de 80 o más Años , Hiperuricemia/tratamiento farmacológico , Adolescente , Incidencia , Adulto JovenRESUMEN
INTRODUCTION: In addition to the well-established understanding of the pharmacogenetics of drug-metabolizing enzymes, there is growing data on the effects of genetic variation in drug transporters, particularly ATP-binding cassette (ABC) transporters. However, the evidence that these genetic variants can be used to predict drug effects and to adjust individual dosing to avoid adverse events is still limited. AREAS COVERED: This review presents a summary of the current literature from the PubMed database as of February 2024 regarding the impact of genetic variants on ABCG2 function and their relevance to the clinical use of the HMG-CoA reductase inhibitor rosuvastatin and the xanthine oxidase inhibitor allopurinol. EXPERT OPINION: Although there are pharmacogenetic guidelines for the ABCG2 missense variant Q141K, there is still some conflicting data regarding the clinical benefits of these recommendations. Some caution appears to be warranted in homozygous ABCG2 Q141K carriers when rosuvastatin is administered at higher doses and such information is already included in the drug label. The benefit of dose adaption to lower possible side effects needs to be evaluated in prospective clinical studies.
Asunto(s)
Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Alopurinol , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Proteínas de Neoplasias , Farmacogenética , Rosuvastatina Cálcica , Humanos , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/genética , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/metabolismo , Rosuvastatina Cálcica/farmacocinética , Rosuvastatina Cálcica/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacocinética , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Alopurinol/farmacocinética , Alopurinol/administración & dosificación , Alopurinol/farmacología , Polimorfismo Genético , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacocinética , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/efectos adversos , Animales , Mutación MissenseAsunto(s)
Alopurinol , Supresores de la Gota , Gota , Humanos , Alopurinol/uso terapéutico , Alopurinol/administración & dosificación , Gota/tratamiento farmacológico , Gota/complicaciones , Supresores de la Gota/administración & dosificación , Supresores de la Gota/uso terapéutico , Masculino , Manía/tratamiento farmacológico , Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/complicaciones , Persona de Mediana EdadRESUMEN
Fifteen New Zealand adult rabbits were randomly allocated into three groups: Sham-operated (group A), Ischemia and Reperfusion (group B) and Carolina Rinse Solution (CRS) (group C). Groups B and C were subjected to one hour of ischemia and two hours of reperfusion. In group C, ten minutes before reperfusion, the bowel lumen was filled with CRS, and the segment immersed in CRS. Necrosis and loss of integrity of the villi were visible in groups B and C. Edema of the submucosa and circular muscle was observed in all groups. Hemorrhage was observed in different layers for groups B and C, but group C showed more severe hemorrhage in different layers during reperfusion. All groups showed polymorphonuclear leukocyte infiltration on the base of the mucosa, submucosa, and longitudinal muscle, in addition to polymorphonuclear leukocytes margination in the mucosal and submucosal vessels. Necrosis of enterocytes, muscles, crypts of Lieberkühn and myenteric plexus was observed in groups B and C during reperfusion. Topical and intraluminal Carolina Rinse Solution did not attenuate the effects of ischemia and reperfusion in the small intestine of rabbits.(AU)
Quinze coelhos da raça Nova Zelândia foram alocados em três grupos: instrumentado (grupo A), isquemia e reperfusão (grupo B) e solução de Carolina rinse (CRS) (grupo C). Os grupos B e C foram submetidos a uma hora de isquemia e a duas horas de reperfusão. No grupo C, 10 minutos antes da reperfusão, o segmento isolado foi imerso e teve seu lúmen preenchido com CRS. Os grupos B e C apresentaram necrose e perda progressiva da integridade das vilosidades. Foi observado edema na submucosa e na camada muscular circular em todos os grupos. Nos grupos B e C, foi observada hemorragia em diferentes camadas, mas, no grupo C, a hemorragia foi mais intensa durante a reperfusão. Todos os grupos apresentaram infiltrado de PMN na base da mucosa, na submucosa e na camada muscular longitudinal e marginação de PMN nos vasos da mucosa e da submucosa. Durante a reperfusão, foi observada necrose dos enterócitos, das camadas musculares, das criptas de Lieberkühn e do plexo mioentérico nos grupos B e C. O uso tópico e intraluminal de CRS não atenuou os efeitos da isquemia e da reperfusão no intestino delgado de coelhos.(AU)
Asunto(s)
Animales , Conejos , Reperfusión/veterinaria , Alopurinol/administración & dosificación , Deferoxamina/administración & dosificación , Glutatión/administración & dosificación , Isquemia/veterinaria , Yeyuno/cirugíaRESUMEN
Abstract Background Benzbromarone is a uricosuric drug that has been used in the treatment of gout over the last 30 years. Due to its potent inhibition of the dominant apical (luminal) urate exchanger in the human proximal tubule URAT1, it reduces the urate reabsorption, diminishing serum urate levels and therefore preventing gout flares. Main body of the abstract Through several clinical trials, Benzbromarone has been proved effective and safe, inclusive in patients with chronic kidney disease and as combination therapy with allopurinol. Due to hepatotoxicity reports, it was withdrawn from the European market by the manufacturer, however many authors have questioned the product's withdrawal due to a lack of clinical evidence in order to support its hepatotoxicity. Benzbromarone is still available in several European countries, New Zealand, Brazil and several other countries. Despite the product's marketing over more than 20 years after the first hepatotoxicity reports, we have found only five reports in our literature search, and no prospective or retrospective study correlating hepatotoxicity with benzbromarone use. Short conclusion Benzbromarone is a safe and effective molecule for the treatment of gout. However, due to in vitro and in vivo data related to hepatotoxicity, it is prudent to prescribe it with some caution, especially for patients with an already known liver condition.
Asunto(s)
Humanos , Benzbromarona/uso terapéutico , Gota/tratamiento farmacológico , Alopurinol/administración & dosificación , Combinación de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con MedicamentosRESUMEN
The standard therapy for some autoimmune diseases consists of a combination of corticosteroids and thiopurines. In non-responders to thiopurine drugs, the measurement of the metabolites of azathioprine, 6-thioguanine, and 6-methylmercaptopurine, can be a useful tool. The measurement has been used during the treatment of inflammatory bowel diseases and, less commonly, in autoimmune hepatitis. Many patients preferentially metabolize thiopurines to 6-methylmercaptopurine (6-MMP), which is potentially hepatotoxic, instead of 6-thioguanine, the active immunosuppressive metabolite. The addition of allopurinol shifts the metabolism of thiopurine towards 6-thioguanine, improving the immunosuppressive effect. We present the case of a 51-year-old female with autoimmune hepatitis who had a biochemical response after azathioprine and prednisone treatment without histological remission, and who preferentially shunted to 6-MMP. After the addition of allopurinol, the patient's 6-thioguanine levels increased, and she reached histological remission with a reduction of 67% of the original dose of azathioprine. The patient did not develop clinical manifestations as a consequence of her increased immunosuppressive state. We also review the relevant literature related to this issue. In conclusion, the addition of allopurinol to thiopurine seems to be an option for those patients who do not reach histological remission and who have a skewed thiopurine metabolite profile.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Alopurinol/administración & dosificación , Azatioprina/administración & dosificación , Hepatitis Autoinmune/tratamiento farmacológico , Inducción de Remisión/métodos , Alopurinol/metabolismo , Azatioprina/administración & dosificaciónRESUMEN
En el presente trabajo se muestran los resultados de un estudio experimental, multicéntrico, no controlado, en el que se ha comprobado la eficacia y seguridad de un extracto seco de Artemisia annua en perros con leishmaniosis. En el estudio participaron 34 perros, que recibieron una dosis media de un extracto seco de Artemisia annua equivalente a 100 mg/kg/12 h de hoja seca, en tandas de 9 días seguidos de descanso de 7 días durante tres meses. 24 de los perros fueron tratados únicamente con el extracto de A. annua, los 10 restantes habían sido tratados con medicación convencional y tras sufrir recaídas se les administró el extracto, sin interrumpir el tratamiento con alopurinol (10 mg/kg/12 h). Los animales fueron analizados al principio del tratamiento y a los tres meses mediante evaluación de los signos clínicos asociados a la enfermedad, análisis de sangre y orina (en los casos que lo requerían), y título de anticuerpos (frente a Leishmania infantum por inmunofluorescencia indirecta). En 24 de ellos, además, se midió la respuesta inmune mediante ELISA y la carga parasitaria a través del método qPCR.En todos los casos se observó una mejora clínica evidente y una disminución de la carga parasitaria, sin apreciarse diferencias significativas entre los casos tratados sólo con el extracto y aquellos que recibieron además alopurinol, excepto una normalización más precoz en el título de anticuerpos en los animales suplementados con alopurinol.La administración del extracto no provocó efectos adversos en ninguno de los animales.En base a los resultados obtenidos A. annua podría postularse como una alternativa terapéutica en leishmaniosis canina
The present work shows the results of an experimental, multicenter, not controlled study in which it has been verified the efficacy and safety of a dry extract of Artemisia annua against leishmaniasis in dogs. Thirty-four dogs participated in the study and received, along three months, a mean dose of Artemisia annua dry extract equivalent to 100 mg/kg/12 h of dry leaf, alternating periods of 9 days of treatment and 7 days of pause. Twenty-four dogs were treated only with the A. annuaextract, while the remaining 10, which were being treated with allopurinol (10 mg/kg/12 h), were additionally administered with the extract after suffering relapses. The animals were analyzed at the beginning of the treatment and at three months by evaluation of the clinical signs associated with the disease, blood and urine analysis (when required), as well as titration of antibodies against Leishmania infantum by indirect immunofluorescence. In 24 of them, immune response by ELISA and parasitic load by qPCR were additionally measured.In all cases, a clinical improvement and a decrease in the parasite load were evidenced, with no significant differences between the cases treated with the extract alone and those that also received allopurinol, except for an earlier normalization of the antibody titer in the latter. The administration of the extract did not cause adverse effects in any of the animals. Based on the results obtained, A. annua extract could be postulated as a therapeutic alternative in canine leishmaniasis
O presente trabalho mostra os resultados de um estudo experimental, multicêntrico e não controlado no qual foi verificado. a eficácia e segurança de um extrato seco de Artemisia annua em cães com leishmaniose.Trinta e quatro cães participaram do estudo e receberam, por três meses, dose média de extrato seco de Artemisia annua equivalente a 100 mg/kg/12 h de folha seca, em lotes de 9 dias, seguidos de 7 dias de repouso. Vinte e quatro dos cães foram tratados apenas com o extrato de A. annua, enquanto os 10 restantes, que estavam sendo tratados com alopurinol (10 mg / kg / 12 h), receberam adicionalmente o extrato após sofrer recaídas. Os animais foram analisados no início do tratamento e aos três meses pela avaliação dos sinais clínicos associados à doença, exames de sangue e urina (nos casos que exigiam), bem como título de anticorpos (contra Leishmania infantum por imunofluorescência indireta ) Em 24 deles, além disso, a resposta imune foi medida por ELISA e a carga parasitária pelo método qPCR.Em todos os casos foi observada melhora clínica evidente e diminuição da carga parasitária, não havendo diferenças significativas entre os casos tratados apenas com o extrato e os que também receberam alopurinol, exceto por uma normalização mais precoce do título de anticorpos nestes últimos. A administração do extrato não causou efeitos adversos em nenhum dos animais. Com base nos resultados obtidos, o extracto de A. annua pode ser postulada como alternativa terapêutica na leishmaniose canina
Asunto(s)
Animales , Masculino , Femenino , Perros , Resultado del Tratamiento , Artemisia annua , Leishmaniasis/terapia , Leishmaniasis/veterinaria , Alopurinol/administración & dosificación , Técnica del Anticuerpo Fluorescente Indirecta , Leishmania infantum , Medición de RiesgoRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Adulto , Litiasis/etiología , Litiasis/genética , Infecciones Urinarias/complicaciones , Alopurinol/administración & dosificación , Insuficiencia Renal Crónica/etiología , Litiasis/diagnóstico , Hematuria/diagnóstico , Litiasis/tratamiento farmacológico , Cateterismo Urinario , Insuficiencia Renal Crónica/genéticaRESUMEN
PURPOSE: To investigate the duration of apoptosis caused by ischemia-reperfusion in the intestine in a new double jejunum-segment model, and to analyze the protective effects of allopurinol or ischemic preconditioning (IPC). METHODS: In Experiment I for harvesting the double jejunum-segment model after laparotomy a 30-cm-long jejunum part was selected on mongrel dogs (n=24). End-to-end anastomoses were performed at both ends and in the middle of the jejunum part, creating two equal segments. In one segment ischemia was induced by occluding the supplying vessels, the other segment served as control. Tissue samples for detecting apoptosis were taken at 30th minutes, 1st, 2nd, 4th, 6th, 8th, 12th and 24th hours of reperfusion. In Experiment II using the same model the 4-hour reperfusion time period, allopurinol (50 mg/kg) pre-treated and IPC (3 cycles of 5x1) groups (n=5 per each) were also investigated. RESULTS: In Experiment I the greatest apoptotic activity was detected at the 4th and 6th hour of reperfusion (14.2 ± 1.31 and 16.3 ± 1.05 per visual field at 40x magnification). In Experiment II Using the 4-hour reperfusion time period allopurinol pre-treatment increased the apoptotic activity (10.72 ± 0.47 per 50 intestinal villi) approximately two-fold than the IPC (6.72 ± 0.46 per 50 intestinal villi) did (p<0.05). CONCLUSIONS: Apoptotic activity has a characteristic time curve, reaching the highest values between the 4th and 6th hours after 30-minute intestinal ischemia. Ischemic preconditioning seemed to be protective against the morphological changes caused by intestinal ischemia-reperfusion.
OBJETIVO: Investigar a duração da apoptose causada pela isquemia-reperfusão no intestino em um novo modelo de duplo segmento de jejuno e analisar os efeitos protetores do alopurinol ou precondicionamento isquêmico (IPC). MÉTODOS: No experimento I para obter o modelo do duplo segmento de jejuno, após a laparotomia, uma parte de 30cm de comprimento de jejuno foi selecionada em cães mestiços (n=24). Anatomoses T-T foram realizadas em ambas as extremidades no meio do segmento de jejuno, criando dois segmentos iguais. Em um segmento foi induzida isquemia por oclusão dos vasos que o irrigavam e o outro segmento foi usado como controle. Amostras de tecido para detecção da apoptose foram obtidos aos 30 minutos, 1h, 2h, 4h, 6h, 8h, 12h e 24 horas de reperfusão. No experimento II usando o mesmo modelo, no tempo de reperfusão de 4 horas, foram investigados dois outros grupos (n=5 cada) usando precondicionamento com alopurinol (50 mg/kg) e IPC (3 ciclos de 5x1). RESULTADOS: No experimento I a maior atividade de apoptose detectada foi às 4h e 6h de reperfusão (14,2 ± 1,31 e 16,3 ± 1,05 no campo visual de 40x). No experimento II usando o período de 4horas de reperfusão o pré-tratamento com alopurinol aumentou a atividade apoptótica (10,72 ± 0,47) aproximadamente 2 vezes mais do que o IPC (6,72 ± 0,46) (p<0,05). CONCLUSÕES: A atividade de apoptose tem uma curva caractetística, atingindo maiores valores entre a 4ª e a 6ª horas após 30 minutos de isquemia intestinal. O precondicionamento isquêmico parece proteger contra alterações morfológicas causadas pela isquemia-reperfusão intestinal.
Asunto(s)
Animales , Alopurinol/administración & dosificación , Perros/clasificación , Isquemia , Yeyuno/anatomía & histologíaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Gota/tratamiento farmacológico , Alopurinol/administración & dosificación , Colchicina/administración & dosificación , Diclofenaco/administración & dosificaciónRESUMEN
INTRODUCTION: The exact mechanism of chronic nonbacterial prostatitis has not been yet elucidated and the outcome with the current management is dismal. In this trial, we studied the effect of allopurinol in the treatment of this disease. MATERIALS AND METHODS: In this randomized double blind controlled trial, a calculated sample size of 56 were grouped into "intervention group" who received allopurinol (100 mg tds for 3 months) with ofloxacin (200 mg tds) for 3 weeks (n = 29) and "control group" who received placebo tablets with ofloxacin (n = 27). PatientsÆ scores based on the National Institute of Health Chronic Prostatitis Symptom Score were recorded before therapy and then every month during the study. A four-glass study was performed before intervention and after 3 months. RESULTS: The 2 groups were similar regarding outcome variables. In the first month of study, a significant but similar improvement in symptom scores was observed in both groups. Microscopic examination of prostate massage and post-massage samples were also similar in both groups. No side effects due to allopurinol were observed in patients. CONCLUSION: We did not find any advantage for allopurinol in the management of chronic prostatitis versus placebo in patients receiving routine antibacterial treatment.
Asunto(s)
Adulto , Humanos , Masculino , Alopurinol/uso terapéutico , Antiinfecciosos Urinarios/uso terapéutico , Antimetabolitos/uso terapéutico , Ofloxacino/uso terapéutico , Prostatitis/tratamiento farmacológico , Alopurinol/administración & dosificación , Antiinfecciosos Urinarios/administración & dosificación , Antimetabolitos/administración & dosificación , Enfermedad Crónica , Método Doble Ciego , Quimioterapia Combinada , Ofloxacino/administración & dosificaciónRESUMEN
La predicción de solubilidad de los principios activos en sistemas codisolventes se estudia para optimizar los procesos tecnológicos de preformulación y resulta clave en procesos de desarrollo e investigación en el diseño farmacéutico racional de medicamentos seguros y eficaces. En este trabajo, algunos métodos de estimación, desarrollados en los últimos años, se han probado con el alopurinol. El alopurinol es un compuesto químico empleado como medicamento frente a la hiperuricemia y sus complicaciones, como la gota. Se obtuvieron excelentes correlaciones entre las solubilidades experimentales y calculadas a 25ºC. Los resultados demuestran la utilidad de estos modelos en preformulación de medicamentos con el fin de reducir el número de experimentaciones, que a menudo consumen tiempo y recursos económicos(AU)
The prediction of solubility of the drugs in co-solvents systems is studied to optimize technological processes of preformulación and it is key in processes of development and research on rational pharmaceutical design of safe and effective medicines. In this work, some methods of estimation, developed in recent years, have been tested with allopurinol. Allopurinol is a drug used primarily to treat hyperuricemia and its complications, including chronic gout. We have obtained excellent correlations between the calculated and experimental solubility at 25 ºC. The results show the usefulness of these models in preformulación from medicines to reduce the number of experiments, which often consume time and resources(AU)
Asunto(s)
Alopurinol/administración & dosificación , Alopurinol/uso terapéutico , Química Farmacéutica/métodos , Química Farmacéutica/tendencias , Alopurinol/farmacología , Alopurinol/farmacocinética , Química Farmacéutica/organización & administración , Química Farmacéutica/normas , Aditivos en SaneantesRESUMEN
A influencia do ion superoxido na evolution da nefropatia por adriamicina foi avaliada usando-se alopurinol para inibir sua sintese.Sessenta ratos Wistar machos foram divididos em 6 grupos.No primeiro dia do experimento 3 grupos receberam salina(GCS,GCSTA eGCSTC) e 3 receberam adriamicina(GNC,GNTA,GNTC)Dois grupos(GCSTA eGNTA)foram tratados com alopurinol 3 horas antes e 1 minuto depois da inoculacao com salina(GCTA) ou adriamicina(GNTA).em dois grupos adicionais o tratamento com alopurinol foi mantido ate o fim do experimento(4 semanas).Os grupos tratados com adriamicina apresentaram proteinuria macica da semana 2 ate a semana 4.Apenas na semana 2 observou-se diferenca estatistica entre a proteinuria dos tres grupos tratados com adriamicina.((GNC=129,2+ou -17,5mg/24h:GNTA=85,4+ ou -15,9mg/24h:GNTC=87,8+ ou -15,9mg/24h;p maior0,01)A microscopia optica os animais inoculados com adriamicina apresentaram somente lesoes tubulo-intersticiais tais como cilindros intratubulares,dilatacao e atrofia tubular e infiltrado inflamatorio intersticial.Nao houve diferenca significativa do indice de lesao tubulo-interstitical entre os tres grupos nefroticos(GNC=8;GNTA=6;GNTC=4;p menor0,05).Conclusao:Em ratos com nefropatia por adriamicina,o uso de alopurinol associou-se com diminuicao transitoria da proteinuria,mas nao alterou a lesao tubulo-intersticial
Asunto(s)
Animales , Ratas , Alopurinol/administración & dosificación , Alopurinol/efectos adversos , Alopurinol/orina , Enfermedades Renales/inducido químicamente , Enfermedades Renales/fisiopatologíaRESUMEN
OBJECTIVE: To evaluate the effects of diet and medication, either isolated or associated, on serum levels of uric acid in patients with hyperuricemia. METHODS: We studied patients from the Hypertension Unit of the University of Goias who had hyperuricemia (men > or = 8.5mg/dL and women > or = 7.5mg/dL). We divided the patients into three groups: G1 (low purine diet), G2 (low purine diet + medication), and G3 (medication only). Patients received allopurinol, 150mg/day titrated up to 300mg/dL when necessary. Patients were evaluated with regards to their lifestyles (diet, smoking, physical, activity, alcohol consumption), uric acid, blood pressure, use of medication, body mass index, cholesterol, and triglyceride. Follow-up took place in weeks 0 (M1), 6 (M2), 12 (M3) during the intervention and in week 36(M4) after the study was completed. RESULTS: Fifty-five patients participated in the study, 31 women, mean age 54.4 + or - 10.6 years, body mass index 28.6 + or - 3.9kg/m². A similar reduction (p<0.001) in uric acid levels occurred in the three intervention groups. In week 36 (M4), after 24 weeks without intervention, a tendency toward elevation of uricemia was noted in G2 and G3, and a continuous drop in uricemia was noted in G1. No significant modifications were observed in the other variables analyzed. CONCLUSION: Considering the cost x benefit relationship, a diet low in purine should be the 1st therapeutic option for controlling hyperuricemia in patients with similar characteristic to the ones presented in this study